Introduction
Barbiturate is a therapeutic option for the treatment of elevated intracranial pressure (eICP) in Traumatic brain injury (TBI) patients. It is used in 20% of the patients in a recent European cohort [1] . But, barbiturate may induce an immunosuppression. Indeed, barbiturate have been shown to induce a decrease in white blood cells in old reports [2] and to be associated to early ventilator associated pneumonia (VAP) [3] ).
Objectives
To assess if barbiturate is a risk factor for VAP in TBI patients.
Methods
We conducted a post-hoc analysis of data obtained from 2 RCTs (Corti-TC and SPIRIT), in which use of barbiturate was prospectively collected. Occurrence of VAP, microbiologically confirmed, was the primary endpoint of these 2 RCTs. We conduct an univariate and multivariate analysis to identify risk factors associated with onset of early (≤7 days) or late (>7 days) VAP. Data are expressed as mean ± SD, medians (Q1-Q3) or Odd Ratio with (95% Confident Intervals).
Results
Among the 441 severe TBI patients (age 39 ± 17 yrs, 135 (80.3%) Male, SAPS II 44.7 ± 11.3, initial Glasgow score 5.7 ± 1.9, ISS 20.5 ± 13.7) included in the 2 RCTs (n = 275 for corti-TC and 166 for Spirit), 183(41%) experienced at least one episode of eICP (ICP>20 mmHg). Among these 183 patients, 138(75%) were treated with barbiturate Patients treated with barbiturate had less ventilator free days at D28 (7 ± 8 days compared to 12 ± 9 for patients with eICP, p = 0.001, and to 13 ± 8 for the entire population, p = 0.001). Survival rate at day 28 was not different in barbiturate treated patients (71(60%) vs 14(64%) patients alive at D28, p = 0.72).
Discussion
In these 2 recent RCTs, barbiturate use was an independent predictive factor for early VAP. This could be linked to the severity of the patients (despite the adjustments done. The absence of association with late pneumonia does not support a prolonged barbiturate induced immunosuppression. The ongoing longitudinal analysis, taking into account the time factor, will probably help to precise if barbiturate is a risk factor for early VAP or not.
